NeuroOne Medical Technologies Corporation

NMTC

$1.63

-1.77%

2026-09-04 10:32:36 EDT-$0.03

Healthcare

Medical - Devices

NASDAQ

Active Trading

NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated ...

Price Action of NMTC

$1.63

-1.77%-$0.03

High—

Low—

52W High-76.6%

Rel. vol—

Interval

Range31m

Volume—SMA5SMA10

—

NeuroOne Medical Technologies Corporation is a specialized medical technology enterprise dedicated to improving surgical care options and outcomes for patients suffering from neurological disorders. The company's core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the ...NeuroOne Medical Technologies Corporation is a specialized medical technology enterprise dedicated to improving surgical care options and outcomes for patients suffering from neurological disorders. The company's core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. The company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator, designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota. As of 2025, the company has 18 employees. NeuroOne is publicly traded on the NASDAQ Capital Market under the symbol NMTC, with an IPO date of March 15, 2018. The company has shown strong revenue growth, with a 105% year-over-year increase in the third quarter of fiscal year 2025 and a gross margin expansion to 53.9%. Despite ongoing investments in research and development, the company maintains a focus on advancing its product pipeline and expanding its market presence.ExpandCollapse

Founded

2009

Employees

CEO

David A. Rosa

Full Name

NeuroOne Medical Technologies Corporation

Sector

Healthcare

Industry

Medical - Devices

ROE

-126.45%

Market Cap

$0.01B

Current Ratio

2.84

WACC

10.29%

ROIC

-172.49%

Contact Information

https://nmtc1.com

952 426 1383

7599 Anagram Drive, Eden Prairie, MN 55344

Key Metrics of NMTC

Snapshot

Latest / TTM · 6 periods

Market Cap

$14.85M

ROCE

-183.5%

EV / EBITDA

-1.77x

-133.6% YoY

FCF Yield

-50.3%

-42.1% YoY

Cash Conversion Cycle

154.1d

Current Ratio

2.84

Quick take

TTM —

Positive CCC

Financial Highlights of NMTC

Profitability trend

Latest / TTM · 6 periods

Gross Margin

55.7%

Net Margin

-71.5%

P/E Ratio

-1.79x

n/a

Debt / Equity

0.02

n/a

Current Ratio

2.84

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of NMTC

Upcoming

Sep 30, 2026In 26 days
FY2026 · Estimated annual results
Est. EPS $-0.74 · Revenue $9.54M · 2 analysts
Dec 30, 2026
Q1 FY2027 · Estimated results
Est. EPS $-0.17 · Revenue $3.36M · 3 analysts
Mar 30, 2027
Q2 FY2027 · Estimated results
Est. EPS $-0.17 · Revenue $3.05M · 1 analysts
Jun 30, 2027
Q3 FY2027 · Estimated results
Est. EPS $-0.18 · Revenue $3.05M · 1 analysts

Recent history

Aug 13, 2026
Q3 FY2026 · Results reported
EPS $-0.28 · Revenue $1.97M
View filing
May 12, 2026
Q2 FY2026 · Results reported
EPS $-0.25 · Revenue $2.39M
View filing
Feb 17, 2026
Q1 FY2026 · Results reported
EPS $-0.17 · Revenue $2.89M
View filing
Dec 17, 2025
FY2025 · Annual results
EPS $-0.54 · Revenue $12.10M
View filing
Aug 14, 2025
Q3 FY2025 · Results reported
EPS $-0.19 · Revenue $1.70M
View filing
Mar 31, 2025
Q2 FY2025 · Results reported
EPS $-0.44 · Revenue $1.39M

Financial Statements of NMTC

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$12.1M	+250.4%	-17.5%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-3.6M	+70.7%	+3.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+67.3%	+115.2%	+11.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-34.9%	+89.9%	-39.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-29.8%	+91.6%	-16.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-2.9M	+73.8%	+19.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-24.1%	+92.5%	+2.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	3.8%	-88.1%	-49.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	4.44x	+112.2%	-35.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$10.8M	+100.9%	-21.3%

Actual vs Estimate

A Sep 30Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.54 vs -0.69	+21.7%	-0.28 vs -0.23	-21.7%
Revenue Surprise	$12.1M vs $8.9M	+36.0%	$2.0M vs $2.0M	-0.4%

Insider Transactions of NMTC

Acquisitions (A)

Since Apr 3, 2026

Disposals (D)

Since Apr 3, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 28, 2026	Johns Emily J.	officer: Chief Administrative Officer	Option to Purchase Common Stock	A	12,500	$1.77
Aug 28, 2026	Volker Christopher	officer: Chief Financial Officer	Option to Purchase Common Stock	A	35,000	$1.77
Aug 28, 2026	Christianson Mark	officer: Market Development Director	Option to Purchase Common Stock	A	12,500	$1.77
Aug 28, 2026	Mertens Steve	officer: Chief Technology Officer	Option to Purchase Common Stock	A	15,000	$1.77
Aug 28, 2026	Rosa David A	director, officer: CEO & President	Option to Purchase Common Stock	A	68,000	$1.77

Earnings Call Transcript of NMTC

1 transcript segments

Q3 2026

Unknown Speaker

Operator: Good day, ladies and gentlemen, and welcome to the NeuroOne Medical Technologies Corporation's Third Quarter Fiscal 2026 Financial Results Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; Chris Volker, the company's Chief Financial Officer; and Dave Wambecke, the company's Chief Business Officer. Before I turn the call over to Mr. Rosa, I'd like to remind you that this conference call will include forward-looking statements within the meaning of the U.S. federal securities laws with respect to future operations, financial results, including events, trends and performance, including our 2026 guidance, which are based on management's beliefs and assumptions as of today's call. Forward-looking statements may involve known and unknown risks, uncertainties and other factors, which may cause actual results to differ materially from those expressed or implied by such statements. See NeuroOne's financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, NeuroOne undertakes no obligation to update such forward-looking statements. With that, I will turn the call over to Mr. Dave Rosa, CEO of NeuroOne. Sir, please go ahead. David Rosa: Thank you, operator, and thank you to everyone for joining us today. I'd like to welcome you to our third quarter fiscal 2026 financial results conference call. Before I begin, I want to first welcome both Chris Volker, the company's Chief Financial Officer; and David Wambecke, the company's Chief Business Officer, as both will be presenting for the first time in their respective roles. Now let's get started with a brief financial summary of the quarter. Product revenue for the OneRF Brain Ablation System in the third quarter of fiscal 2026 grew 16% year-over-year to $2 million compared to $1.7 million in the third quarter of fiscal 2025. Orders for the quarter totaled $2.7 million, and we expect aggregate fiscal year 2026 product orders of approximately $11.2 million. Recognized revenue for the fiscal year is expected to be between $9.2 million to $10.5 million, depending on the timing of shipment of those orders. We are working closely with our suppliers to expedite manufacturing in order to address any remaining backlog by the end of the fourth calendar quarter of 2026. Moving forward, we are working towards the qualification of a second manufacturing site, which will increase capacity and potentially reduce lead times. We also saw gross margins expand to 59.9% during the quarter compared to 53.9% year-over-year due to a favorable product mix. More recently, following the end of the quarter, our lead investor also increased their holdings from 7.4% to 12.5%. Moving on from current revenue growth, let's discuss future growth opportunities and new geographical markets. As you may recall from previous releases, the company has been pursuing ISO …

Leadership Team of NMTC

9 executives

Name	Title	Compensation	Gender	Year Born	Status
David A. Rosa	President, Chief Executive Officer & Director	USD 787,079	Male	1964	Active
Christopher R. Volker	Chief Financial Officer	USD 405,733	Male	—	Active
Ronald W. McClurg	Senior Advisor	USD 401,370	Male	1958	Active
Steven Mertens	Chief Technology Officer	USD 332,263	Male	1963	Active
Mark Christianson	Co-Founder, Business Development Director & Medical Sales Liaison	USD 260,848	Male	1967	Active
David J. Wambeke	Chief Business Officer	—	Male	1984	Active
Hijaz Haris	Vice President of Marketing	—	Male	—	Active
Emily Johns	Chief Administrative Officer & General Counsel	—	Female	1991	Active
Parag G. Patil	Chief Medical Advisor	—	—	—	Active

Recent News of NMTC

Seeking Alpha8/13/2026Neutral